Literature DB >> 33170105

A Single-Center Retrospective Analysis of Periprocedural Variables Affecting Local Tumor Progression after Radiofrequency Ablation of Colorectal Cancer Liver Metastases.

Kichang Han1, Jin Hyoung Kim1, Seul Gi Yang1, Seong Ho Park1, Hyun-Kyung Choi1, Seng-Yong Chun1, Pyo Nyun Kim1, Jihong Park1, Myeongjee Lee1.   

Abstract

Background Local tumor progression (LTP) is associated with poorer survival in patients undergoing radiofrequency ablation (RFA) for colorectal liver metastasis (CLM). An algorithmic strategy to predict LTP may help in selection of patients who would benefit most from RFA for CLM. Purpose To estimate local tumor progression-free survival (LTPFS) following RFA of CLM and develop an algorithmic strategy based on clinical variables. Materials and Methods In this retrospective study, between March 2000 and December 2014, patients who underwent percutaneous RFA for CLM were randomly split into development (60%) and internal validation (40%) data sets. Kaplan-Meier method was used to estimate LTPFS and overall survival (OS) rates. Independent factors affecting LTPFS in the development data set were investigated by using multivariable Cox proportional hazard regression analysis. Risk scores were assigned to the risk factors and applied to the validation data set. Results A total of 365 patients (mean age, 60 years ± 11 [standard deviation]; 259 men) with 512 CLMs were evaluated. LTPFS and OS rates were 85% and 92% at 1 year, 73% and 41% at 5 years, 72% and 30% at 10 years, and 72% and 28% at 15 years, respectively. Independent risk factors for LTP included tumor size of 2 cm or greater (hazard ratio [HR], 3.8; 95% CI: 2.3, 6.2; P < .001), subcapsular tumor location (HR, 1.9; 95% CI: 1.1, 3.1; P = .02), and minimal ablative margin of 5 mm or less (HR, 11.7; 95% CI: 4.7, 29.2; P < .001). A prediction model that used the risk factors had areas under the curve of 0.89, 0.92, and 0.90 at 1, 5, and 10 years, respectively, and it showed significantly better areas under the curve when compared with the model using the minimal ablative margin of 5 mm or less alone. Conclusion Radiofrequency ablation provided long-term control of colorectal liver metastases. Although minimal ablative margin of 5 mm or less was the most dominant factor, the multifactorial approach including tumor size and subcapsular location better predicted local tumor progression-free survival. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Soulen and Sofocleous in this issue.

Entities:  

Mesh:

Year:  2020        PMID: 33170105     DOI: 10.1148/radiol.2020200109

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis.

Authors:  Emily A Knott; Timothy J Ziemlewicz; Sam J Lubner; John F Swietlik; Sharon M Weber; Annie M Zlevor; Colin Longhurst; J Louis Hinshaw; Meghan G Lubner; Daniel L Mulkerin; Daniel E Abbott; Dustin Deming; Noelle K LoConte; Nataliya Uboha; Allison B Couillard; Shane A Wells; Paul F Laeseke; Marci L Alexander; Fred T Lee
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases.

Authors:  Nikiforos Vasiniotis Kamarinos; Mithat Gonen; Vlasios Sotirchos; Elena Kaye; Elena N Petre; Stephen B Solomon; Joseph P Erinjeri; Etay Ziv; Assen Kirov; Constantinos T Sofocleous
Journal:  Int J Hyperthermia       Date:  2022       Impact factor: 3.753

3.  Transforming Commercial Copper Sulfide into Injectable Hydrogels for Local Photothermal Therapy.

Authors:  Xiaoran Wang; Zizhen Yang; Zhaowei Meng; Shao-Kai Sun
Journal:  Gels       Date:  2022-05-20

4.  Interstitial Optical Monitoring of Focal Laser Ablation.

Authors:  Rory Geoghegan; Le Zhang; Alan Priester; Holden H Wu; Leonard Marks; Shyam Natarajan
Journal:  IEEE Trans Biomed Eng       Date:  2022-07-18       Impact factor: 4.756

5.  Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?

Authors:  Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Sho Fujisawa; Mithat Gonen; Ning Fan; Yevgeniy Romin; Richard K G Do; Etay Ziv; Joseph P Erinjeri; Elena N Petre; Vlasios S Sotirchos; Juan C Camacho; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous
Journal:  J Vasc Interv Radiol       Date:  2021-11-17       Impact factor: 3.682

6.  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions.

Authors:  Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini
Journal:  Eur Thyroid J       Date:  2021-05-25

Review 7.  The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease.

Authors:  Dimitrios K Filippiadis; Georgios Velonakis; Alexis Kelekis; Constantinos T Sofocleous
Journal:  Diagnostics (Basel)       Date:  2021-02-14

Review 8.  Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward.

Authors:  Yuan-Mao Lin; Iwan Paolucci; Kristy K Brock; Bruno C Odisio
Journal:  Cancers (Basel)       Date:  2021-08-04       Impact factor: 6.639

9.  Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Gun Ha Kim; Pyeong Hwa Kim; Jin Hyoung Kim; Pyo-Nyun Kim; Hyung Jin Won; Yong Moon Shin; Sang Hyun Choi
Journal:  Eur Radiol       Date:  2021-08-04       Impact factor: 5.315

10.  Comparison of Percutaneous Radiofrequency Ablation for Subcapsular and Non-Subcapsular Colorectal Cancer Liver Metastases.

Authors:  Hongjie Fan; Xiaoyan Wang; Jiali Qu; Wei Lu; Shufeng Xu; Xia Wu; Jingya Xia; Yanhua Zhang; Jihong Sun; Xiaoming Yang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.